Kakarla V Chalam Ravi K Murthy Shailesh K Gupta Vikram S Brar
10.4103/0301-4738.73712
Indian J Ophthalmol
2011 Jan-Feb;59(1):47-8.
CC BY
https://pubmed.ncbi.nlm.nih.gov/21157072/
Angiogenesis Inhibitors / administration & dosage Angiogenesis Inhibitors / adverse effects Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal / adverse effects Retinal Perforations / chemically induced Retinal Perforations / diagnosis Tomography, Optical Coherence
Angiogenesis Inhibitors / administration & dosage Angiogenesis Inhibitors / adverse effects Antibodies, Monoclonal / administration & dosage Antibodies, Monoclonal / adverse effects Retinal Perforations / chemically induced Retinal Perforations / diagnosis Tomography, Optical Coherence Case Reports Aged Antibodies, Monoclonal, Humanized Bevacizumab Female Fundus Oculi Humans Intravitreal Injections Macular Degeneration / complications Macular Degeneration / drug therapy Macular Degeneration / physiopathology Vision Disorders / etiology Visual Acuity Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Bevacizumab
PMC3032242
21157072
Spectral domain optical coherence tomography features of multiple subfoveal retinal pigment epithelial tears after intravitreal bevacizumab
2011